Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Creabilis Itching To Start Phase III Tests Of Lead Asset For Chronic Pruritus

This article was originally published in Scrip

Executive Summary

Keen to make up for lost time, dermatology specialist Creabilis Ltd is using positive Phase IIb data to advance its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, on to Phase III trials in psoriasis patients which, if successful, should open the way for regulatory filing in mid-2018 for a condition where there is no approved standard of care.

You may also be interested in...

Itch-Focused Creabilis Finally Secures Its Future Through US Sale

Creabilis has finally secured the future of its Phase III-ready psoriatic itch candidate CT327 – through a sale of the company to young US firm Sienna Biopharmaceuticals.

Regeneron Revives NGF Inhibitor With Phase II/III Data; Safety Issue Remains

Regeneron Pharmaceuticals Inc. reported statistically significant pain relief for osteoarthritis sufferers enrolled in the company's Phase II/III clinical trial for fasinumab, but the data didn't relieve concerns about neuro-musculoskeletal side effects for medicines that inhibit nerve growth factor (NGF).

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts